Label-free ADAM10 capacitive assay for the early diagnosis of Alzheimer's disease

Abstract

This study demonstrates a quantum capacitance-based approach using a peptide-redox-active interface modified with Ab1 and Ab2 ADAM10 isoform antibodies for the development of label-free and point-of-care assays that enable high-accuracy quantification of the target analyte in plasma samples. The sensitivity of the quantum capacitance to changes in interface energy upon analyte binding suggests significant potential for creating miniaturized diagnostic devices for non-communicable diseases, including Alzheimer's disease.